NYSE · COHRHealthcareOptical Instruments

Coherent financials

$291.26+3.12%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ4 '26
Jun 30
Q3 '26
Mar 31
Q2 '26
Dec 31
Q1 '26
Sep 30
Q4 '25
Jun 30
Q3 '25
Mar 31
Q2 '25
Dec 31
Q1 '25
Sep 30
Q4 '24
Jun 30
Q3 '24
Mar 31
Q2 '24
Dec 31
Q1 '24
Sep 30
Revenue$2.05B$1.81B$1.69B$1.58B$1.53B$1.50B$1.43B$1.35B$1.31B$1.21B$1.13B$1.05B
Gross profit$787.1M$679.9M$622.8M$579.2M$546.1M$527.7M$509.4M$460.1M$431.9M$366.5M$350.6M$306.9M
Gross margin38.5%37.7%36.9%36.6%35.7%35.2%35.5%34.1%32.9%30.3%31.0%29.1%
Operating income$319.6M$220.0M$184.0M$143.9M-$8.4M$67.2M$136.9M$75.2M$63.2M$22.3M$37.3M-$15.0M
Net income$240.5M$191.4M$145.1M$192.9M-$128.8M-$17.0M$71.1M-$5.9M-$79.9M-$44.4M-$57.6M-$97.7M
Net margin11.8%10.6%8.6%12.2%−8.4%−1.1%5.0%−0.4%−6.1%−3.7%−5.1%−9.3%
Diluted EPS$1.19$0.97$0.76$1.19$-0.86$-0.11$0.44$-0.04$-0.52$-0.29$-0.38$-0.65
EBITDA$510.5M$387.3M$324.6M$294.7M$265.4M$287.5M$279.3M$237.3M$77.3M$173.6M$173.7M$126.3M
Operating cash flow$69.5M-$93.8M$57.9M$46.0M$130.3M$163.0M$187.4M$153.0M$162.3M$117.4M$67.2M$198.8M
Free cash flow-$486.2M-$383.5M-$95.7M-$58.0M-$1.1M$51.1M$81.7M$61.0M$62.4M$24.2M-$24.3M$136.6M
Diluted shares201.7M196.4M192.8M190.7M150.2M155.2M160.0M153.6M152.5M152.1M151.6M150.3M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30Mar 31
Cash & equivalents$1.16B$1.59B$863.7M$852.8M$909.2M$890.3M
Short-term investments$825.0M$825.0M$0.00$0.00$0.00$0.00
Total debt$3.22B$3.19B$3.35B$3.31B$3.69B$3.73B
Total assets$18.30B$17.29B$15.09B$14.70B$14.91B$14.44B
Total liabilities$7.06B$6.27B$6.20B$6.01B$6.43B$6.28B
Shareholders' equity$11.24B$11.02B$8.89B$6.18B$6.00B$5.71B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology